Jacobson Pharma Corporation Limited (2633) and JBM Healthcare Limited (02161) have jointly announced the renewal of continuing connected transactions through new agreements (the “2026 Framework Agreements”). These agreements will take effect upon the expiry of their existing arrangements on 31 March 2026 and will cover a term from 1 April 2026 to 31 March 2029.

Under the 2026 Logistics Services Agreement, the Jacobson Group will continue providing logistics services to the JBM Group. The annual caps for these services are set at HK$8.00 million, HK$9.00 million, and HK$10.00 million for the years ending 31 March 2027, 2028, and 2029, respectively. Pricing remains based on the Jacobson Group’s cost plus a 10.0% margin.

Meanwhile, the 2026 Manufacturing Services Agreement covers the production of selected generic drugs by the JBM Group for the Jacobson Group. Annual caps for these fees stand at HK$7.00 million, HK$8.00 million, and HK$9.00 million for the years ending 31 March 2027, 2028, and 2029, respectively, determined using manufacturing costs plus a 15.0% margin.

The renewed agreements constitute continuing connected transactions under Chapter 14A of the Listing Rules. Given that the highest applicable percentage ratios for the annual caps exceed 0.1% but remain below 5.0%, the transactions only require reporting, announcement, and annual review, without needing a circular or independent shareholders’ approval. Both boards consider these terms to be fair and reasonable and view the agreements as beneficial to each group’s operational and financial interests.